Low-Dose CT Screening for Lung Cancer

Eligibility Criteria for LDCT Screening

• The American College of Chest Physicians recommends annual screening for lung cancer with low-dose CT for high-risk individuals aged 55 to 80 years with a 30 pack-year smoking history who currently smoke or have quit within the past 15 years 1, 2
• Individuals aged 55-80 years with ≥30 pack-year smoking history who currently smoke or have quit within the past 15 years are eligible for LDCT screening, according to the American Journal of Respiratory and Critical Care Medicine 1, 3
• Screening should be discontinued once a person has not smoked for 15 years, as recommended by the American Journal of Respiratory and Critical Care Medicine 1
• Screening should be discontinued if the person develops a health problem that substantially limits life expectancy or the ability/willingness to have curative lung surgery, according to the American Journal of Respiratory and Critical Care Medicine 1
• Individuals aged 50-80 years with ≥20 pack-year smoking history who currently smoke or have quit within the past 15 years may be eligible for LDCT screening, based on the 2021 USPSTF update 4
• Individuals with high risk based on validated clinical risk prediction calculators, such as the PLCOm2012 calculator with a 6-year risk threshold of 1.51%, may be eligible for LDCT screening, according to the American College of Chest Physicians 5, 4

Contraindications for Screening

• Individuals with significant comorbidities that limit life expectancy or ability to tolerate evaluation/treatment of screen-detected findings should not undergo LDCT screening, as recommended by the American College of Chest Physicians 5
• Symptomatic individuals should instead receive appropriate diagnostic testing, according to the American College of Chest Physicians 5
• Individuals who have quit smoking more than 15 years ago and don't meet other high-risk criteria should not undergo LDCT screening, as recommended by the American College of Chest Physicians 5

Technical Specifications for LDCT Screening

• Screening should use a low-dose CT multidetector scanner with the following parameters: 120-140 kVp, 20-60 mAs, average effective dose of 1.5 mSv or less, and collimation of 2.5 mm or less, as recommended by the Journal of Thoracic Oncology 6

Management of Screen-Detected Nodules

• Nodule size ≥5 mm indicates a positive result requiring 3-month follow-up CT, according to the Journal of Thoracic Oncology 6
• Nodules ≥15 mm should undergo immediate further diagnostic procedures, as recommended by the Journal of Thoracic Oncology 6
• Follow-up CT of a nodule should be done as a limited LDCT scan, covering only the nodule area, according to the Journal of Thoracic Oncology 6

Potential Harms and Limitations

• Radiation exposure from repeated annual scans contributes to cumulative exposure, as noted by the Journal of Thoracic Oncology 2
• There is a potential for overdiagnosis of indolent cancers, according to the American Journal of Respiratory and Critical Care Medicine 1
• Possible complications from invasive diagnostic procedures following positive screens are a concern, as noted by the American Journal of Respiratory and Critical Care Medicine 1

Implementation Considerations

• Screening should be performed in centers with multidisciplinary expertise in lung cancer diagnosis and treatment, as recommended by the Journal of Thoracic Oncology 6
• Smoking cessation counseling should be provided alongside screening, as screening is not a substitute for smoking cessation, according to the American Journal of Respiratory and Critical Care Medicine 3
• Lung cancer screening should not be considered a substitute for smoking cessation, as recommended by the American Journal of Respiratory and Critical Care Medicine 3

Key Caveats

• Patients with a strong clinical suspicion of stage I or II lung cancer based on risk factors and radiologic appearance may proceed directly to surgery without a preoperative biopsy, according to the Journal of the National Comprehensive Cancer Network 7
• Individuals who do not meet screening criteria but have symptoms suggestive of lung cancer should receive appropriate diagnostic testing rather than screening, as recommended by the American College of Chest Physicians 5

Low-Dose CT Screening for Lung Cancer Guidelines

Eligibility and Screening Criteria

• The American College of Chest Physicians recommends that symptomatic individuals suggesting possible lung cancer, such as those with cough, hemoptysis, weight loss, or chest pain, should not be screened and instead require diagnostic testing 8
• The National Lung Screening Trial (NLST) used older criteria, including age 55-80 years with ≥30 pack-years, which is now outdated 9, 10

Technical Specifications for LDCT

• The American College of Radiology recommends using a multidetector CT scanner with minimum 4 channels, 120-140 kVp voltage, and 20-60 mAs current to minimize radiation exposure while maintaining diagnostic quality 11, 12, 13
• The average effective dose should be ≤1.5 mSv, and collimation should be ≤2.5 mm 11, 12, 13

Screening Interval and Management of Screen-Detected Nodules

• The Journal of Thoracic Oncology suggests performing annual screening after the initial baseline scan, with some guidelines recommending transitioning to biennial screening after 2 consecutive negative annual scans 11, 12
• Nodules ≥5 mm should trigger 3-month follow-up LDCT, reducing false positives compared to the NLST's 4mm threshold while maintaining cancer detection 11, 12, 13

Implementation Requirements and Key Harms

• Screening programs should develop systematic strategies to identify symptomatic patients who need diagnostic rather than screening protocols, and provide smoking cessation counseling alongside screening 8
• Cumulative radiation from annual screening over decades contributes to lifetime exposure, but using proper low-dose technique and limited follow-up scans minimizes this risk 11
• Even with optimized thresholds, expect false-positive rates requiring additional imaging or procedures, and overdiagnosis of indolent cancers that would never become clinically significant occurs in screening populations 11, 12

Critical Caveats

• The 20% lung cancer mortality reduction demonstrated in NLST applies specifically to the high-risk population meeting eligibility criteria, and benefits only outweigh harms when screening is implemented in strictly controlled programs with appropriate expertise and follow-up protocols 9, 10, 14

Lung Cancer Screening Guidelines

Screening Modalities

• The National Comprehensive Cancer Network recommends that PET scan is not a screening tool, but rather reserved for diagnostic evaluation of suspicious lesions already identified 15
• The American Thoracic Society suggests that screening should only be performed in high-quality centers with multidisciplinary teams including thoracic radiology, pulmonology, and thoracic surgery, as well as expertise in LDCT interpretation and lung nodule management 16, 15

Implementation Requirements

• The National Comprehensive Cancer Network guidelines state that high-quality centers performing screening should have access to comprehensive diagnostic and treatment services 16, 15